MOUNJARO 10 mg/.5mL (Tirzepatide INJECTION, SOLUTION) 10 mg/.5mL

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It enhances insulin secretion and reduces glucagon levels in a glucose-dependent manner, thereby lowering fasting and postprandial glucose concentrations, decreasing food intake, and reducing body weight in patients with type 2 diabetes mellitus.

The usual starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. The dosage can be increased in 2.5 mg increments after at least 4 weeks on the current dose, up to a maximum of 15 mg for adults and 10 mg for pediatric patients 10 years of age and older. The prescriber will determine the appropriate dosage based on individual patient needs.

Based on animal studies, MOUNJARO may cause fetal harm. It is not recommended for use during pregnancy. The safety of MOUNJARO during breastfeeding has not been established. Patients should consult their healthcare provider for personalized advice.

To order MOUNJARO 10 mg/0.5mL from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then provide pricing, availability, shipping, and the necessary import paperwork.

MOUNJARO 10 mg/0.5mL is a dual GIP and GLP-1 receptor agonist, which distinguishes it from other diabetes medications that may target only one of these pathways. Its unique mechanism of action can provide additional benefits in glycemic control and weight reduction compared to other treatments.

MOUNJARO 10 mg/0.5mL should be stored in the refrigerator at 2°C to 8°C (36°F to 46°F). If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to a total of 21 days. Do not freeze MOUNJARO and protect it from heat and light.

MOUNJARO 10 mg/0.5mL is administered subcutaneously once weekly. It can be injected in the abdomen, thigh, or back of the upper arm. The injection site should be rotated with each dose. Patients should follow the instructions provided by their healthcare provider for proper administration.

The most serious risks associated with MOUNJARO 10 mg/0.5mL include acute pancreatitis, severe hypoglycemia when used with insulin secretagogues or insulin, hypersensitivity reactions, acute kidney injury due to volume depletion, and severe gastrointestinal adverse reactions. Patients should seek immediate medical attention if they experience any of these symptoms.

MOUNJARO 10 mg/0.5mL should not be used by patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It is also not recommended for patients with severe gastroparesis or a history of severe gastrointestinal disease. Patients should consult their healthcare provider to determine if MOUNJARO is appropriate for them.